• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 161

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

It’s Time to Push Back: Meta’s War on Psychedelic Voices

Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application...

PT311 – William Leonard Pickard – LSD, Fentanyl, Prison, and the...

Psychedelic Bulletin: Numinus to Enter U.S. Clinics Market; Mydecine Announces Reverse...

MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results...

Filament Health Is Issued Patent By United States Patent And Trademark...

Cybin Announces Publication of International PCT Patent Application for Inhalation Delivery...

Awakn Life Sciences Provides Shareholder Update on Three Operational Ketamine-Assisted Therapy...

PharmaTher Signs Exclusive Worldwide License Agreement for Patented Formulation and Production...

Filament Health Announces Pre-ind Meeting With United States Food And Drug...

Numinus Wellness Inc. Reports Q2 2022 Results

1...160161162...291Page 161 of 291

EDITOR PICKS

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©